PPARD and pulmonary arterial hypertension: Whereas no synthetic PPARδ ligand has been approvedby the FDA for clinical use, iloprost (which activates PGI2 receptorand PPARδ) is approved by the FDA to treat pulmonary hypertension andperipheral vascular disease.